Class A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Subclass 3/10: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) for glucose homeostasis (pancreatic hormones A61P 5/48) for hyperglycaemia, e.g. antidiabetics
| Patent # | Title | Filing Date | Issue Date | Patent Owner |
|---|---|---|---|---|
| 12263200 | Specific nutritional or therapeutic agent including a mixture of grape and blueberry | Feb 03, 22 | Apr 01, 25 | ACTIV'INSIDE; SPECIALITES PET FOOD; Universite Laval; Institut National de la Recherche Scientifique (INRS); |
| 12263202 | Method of treating melanocortin-4 receptor pathway-associated disorders | Feb 09, 21 | Apr 01, 25 | RHYTHM PHARMACEUTICALS, INC. |
| 12264186 | Human hepatocyte growth factor mutant and uses thereof | Jan 02, 20 | Apr 01, 25 | BEIJING NORTHLAND BIOTECH. CO., LTD. |
| 12264150 | NR4A1 ligands, pharmaceutical compositions, and related methods of use | Oct 26, 21 | Apr 01, 25 | The Texas A&M University System |
| 12257217 | Compositions and methods for treating hyperphagia in prader-willi syndrome | Oct 15, 22 | Mar 25, 25 | Purdue Research Foundation |
| 12257270 | Treatment of immune disorders | Jul 22, 22 | Mar 25, 25 | Mesoblast International Sarl |
| 12257271 | sp. bacterium and use thereof | Dec 24, 19 | Mar 25, 25 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) |
| 12257287 | Glucagon-derived peptide and use thereof | Nov 12, 19 | Mar 25, 25 | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. |
| 12257308 | Stimuli-responsive PEG-like polymer-based drug delivery platform | Apr 30, 19 | Mar 25, 25 | Duke University |
| 12257309 | Zwitterionic polymer-insulin compositions and related methods | Jan 05, 22 | Mar 25, 25 | Wayne State University |
| 12258367 | Glucoside derivative that acts as SGLT1 inhibitor and application thereof | Mar 30, 20 | Mar 25, 25 | MEDSHINE DISCOVERY INC. |
| 12251385 | Covalent inhibitors of menin-MLL interaction for diabetes mellitus | Aug 10, 22 | Mar 18, 25 | BIOMEA FUSION, INC. |
| 12253527 | Compositions and methods for treating age-related diabetes and related disorders | Jul 19, 22 | Mar 18, 25 | Salk Institute for Biological Studies |
| 12252516 | Mucoadhesive microorganism | Jun 06, 22 | Mar 18, 25 | INTREXON ACTOBIOTICS N.V. |
| 12252522 | Myokines for treating cell proliferative and metabolic diseases and disorders | Jan 06, 23 | Mar 18, 25 | Northwestern University |
| 12245623 | Olive oil enriched with oleanolic acid, process for its preparation and use thereof | Jul 08, 19 | Mar 11, 25 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC); SERVICIO ANDALUZ DE SALUD; |
| 12239630 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | Apr 07, 23 | Mar 04, 25 | Bayer Pharma Aktiengesellschaft |
| 12239660 | Therapeutic composition and methods | Sep 25, 23 | Mar 04, 25 | Viscera Labs, Inc. |
| 12239674 | LRH05 isolate, and composition including the same and use thereof | Jun 17, 21 | Mar 04, 25 | SYNBIO TECH INC. |
| 12239739 | Oral dosing of GLP-1 compounds | Mar 22, 19 | Mar 04, 25 | Novo Nordisk A/S |
| Publication # | Title | Filing Date | Pub Date | Patent Owner |
|---|---|---|---|---|
| 2025/0114,431 | COMPOUND, COMPOSITION AND METHODS FOR LOWERING CIRCULATING GLUCOSE | Oct 10, 23 | Apr 10, 25 | Not available |
| 2025/0114,436 | DYNAMIC-COVALENT HYDROGELS WITH GLUCOSE-SPECIFIC AND GLUCOSE-RESPONSIVE DIBORONATE CROSSLINKING | Feb 08, 23 | Apr 10, 25 | Not available |
| 2025/0115,654 | PHARMACEUTICAL COMPOSITION OF GLP-1 RECEPTOR AND GIP RECEPTOR DUAL AGONIST, AND USE THEREOF | Nov 11, 22 | Apr 10, 25 | Not available |
| 2025/0115,672 | CANINE ANTI-NGF ANTIBODIES AND METHODS OF TREATING PAIN THEREOF | Jun 13, 24 | Apr 10, 25 | Not available |
| 2025/0108,032 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | Sep 26, 24 | Apr 03, 25 | Lexicon Pharmaceuticals Inc. |
| 2025/0108,065 | METHODS OF TREATING PREDIABETES OR REDUCING THE RISK OF DEVELOPING TYPE 2 DIABETES WITH DAPAGLIFLOZIN | Jan 25, 23 | Apr 03, 25 | Not available |
| 2025/0108,072 | NON-NATURALLY OCCURING THREE-DIMENSIONAL (3D) BROWN ADIPOSE-DERIVED STEM CELL AGGREGATES, AND METHODS OF GENERATING AND USING THE SAME | Sep 10, 24 | Apr 03, 25 | Not available |
| 2025/0108,078 | MECHANISTIC BACTERIAL EFECTOR TO PREVENT APOPTOSIS OF HUMAN BETA CELLS | Dec 12, 24 | Apr 03, 25 | Not available |
| 2025/0108,089 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, AND METHODS FOR ENRICHING MRNA CODING FOR SECRETED PROTEINS | Sep 18, 24 | Apr 03, 25 | Not available |
| 2025/0109,168 | POLYPEPTIDE AND USE THEREOF IN REGULATING BLOOD GLUCOSE LEVEL AND/OR REDUCING FAT | Sep 24, 24 | Apr 03, 25 | Not available |
| 2025/0099,411 | Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators | Apr 24, 24 | Mar 27, 25 | Institut Pasteur de Montevideo; Universidad de la República; |
| 2025/0099,562 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS | Dec 06, 24 | Mar 27, 25 | The University of Toledo |
| 2025/0090,529 | USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE | Aug 20, 24 | Mar 20, 25 | Not available |
| 2025/0090,595 | THERAPEUTIC USE OF CANCER-ASSOCIATED FIBROBLAST-ENCAPSULATED PANCREATIC BETA CELLS FOR TREATING DIABETES | Sep 13, 24 | Mar 20, 25 | Not available |
| 2025/0090,596 | MODULATING INFLAMMATION ASSOCIATED WITH FOREIGN BODY RESPONSE | Sep 14, 24 | Mar 20, 25 | Not available |
| 2025/0092,041 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | Nov 22, 24 | Mar 20, 25 | Chugai Seiyaku Kabushiki Kaisha |
| 2025/0082,731 | TRANSDERMAL INSULIN FORMULATIONS AND METHODS OF USE THEREOF | Sep 08, 22 | Mar 13, 25 | Transdermal Delivery Solutions Corp. (d.b.a. HypoSpray Pharma) |
| 2025/0082,781 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | Dec 28, 22 | Mar 13, 25 | Salk Institute for Biological Studies |
| 2025/0082,642 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | Nov 27, 24 | Mar 13, 25 | Not available |
| 2025/0073,283 | STREPTOCOCCUS FOR USE IN THE TREATMENT OF GLUCOSE INTOLERANCE | Oct 06, 21 | Mar 06, 25 | Not available |
| Upgrade to the Professional Level to view Top Owners for this Subclass.Learn More |
|---|
